メンバー

スタッフ

English Information

おおば こうじ

大庭 幸治准教授  

OBA Koji

情報学環・学際情報学府;公共健康医学専攻 生物統計学分野

oba [at] epistat.m.u-tokyo.ac.jp

研究

メタアナリシス、代替エンドポイントの評価、因果推論

経歴

2003.03 東京大学医学部健康科学・看護学科卒業
2005.03 東京大学大学院医学系研究科 健康科学・看護学専攻 博士前期課程修了
2005.04 京都大学大学院医学研究科 社会健康医学系専攻 疫学研究情報管理学分野 助手
2006.10 京都大学大学院医学研究科 EBM研究センター 特任助教(2009年10月より、同センター 特定助教)
2010.04 北海道大学 北海道大学病院 高度先進医療支援センター 助教
2011.09 京都大学学位取得(社会健康医学)
2011.12 北海道大学 北海道大学病院 高度先進医療支援センター データ管理部門 部門長/ 講師
    (2012年10月ー2013年10月 キュリー研究所(フランス)、ハッセルト大学(ベルギー) 客員研究員)
2014.07 東京大学大学院医学系研究科 公共健康医学専攻 生物統計学分野 准教授
2014.08 東京大学大学院 情報学環・学際情報学府 准教授 (配置換)
    東京大学大学院医学系研究科 公共健康医学専攻 生物統計学分野 准教授(兼担)

2016年度 東京大学卓越研究員

活動

日本計量生物学会(2015- 評議員)╱ 日本臨床試験学会╱ 日本癌治療学会

現在、若手研究(A)[JSPS科研費 JP15617613]の助成を受けて、進行再発胃がん/術後胃がんを対象とした臨床試験の個人データに基づくメタアナリシスプロジェクト(GASTRIC project)を実施しています。詳細は下記をご覧ください。https://gastricproject.org/

  1. Aoyama T, Kashiwabara K, Oba K, Honda M, Sadahiro S, Hamada C, Maeda H, Mayanagi S, Kanda M, Sakamoto J, Saji S, Yoshikawa T. Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials. Cancer Medicine 2017; 6(11): 2523-2530. Doi: 10.1002/cam4.1126.
  2. Aoyama T, Oba K, Honda M, Sadahiro S, Hamada C, Mayanagi S, Kanda M, Maeda H, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T. Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients’ data from three large phase III randomized trials. Cancer Med 2017 Jun 22. DOI: 10.1002/cam4.1126
  3. Aoyama T, Sato T, Hayashi T, Yamada T, Cho H, Ogata T, Oba K, Yoshikawa T. Does a laparoscopic approach attenuate the body weight loss and lean body mass loss observed in open distal gastrectomy for gastric cancer? a single-institution exploratory analysis of the JCOG 0912 phase III trial. Gastric Cancer. 2017 Jun 16. doi: 10.1007/s10120-017-0735-4. [Epub ahead of print]
  4. Kusano M, Honda M, Okabayashi K, Akimaru K, Kino S, Tsuji Y, Watanabe M, Suzuki S, Yoshikawa T, Sakamoto J, Oba K, Saji S. Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29-0003. J Cancer Res Ther 2017;13(1):84-90.
  5. Kotake M, Aoyama T, Munemoto Y, Doden K, Kataoka M, Kobayashi K, Nishimura G, Fujita H, Nakamura K, Takehara A, Tanaka C, Sakamoto J, Nagata N, Oba K, Kondo K. Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial). Oncol Lett 2017;13(2):747-753.
  6. Ishiguro N, Koseki N, Kaiho M, Ariga T, Kikuta H, Togashi T, Oba K, Morita K, Nagano N, Nakanishi M, Hara K, Hazama K, Watanabe T, Yamanaka T, Sasaki S, Furuyama H, Shibata M, Shida S, Ishizaka A, Tabata Y, Aoyagi H, Naito H, Yoshioka M, Horino A, Kenri T; Hokkaido Pediatric Respiratory Infection Study Group. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. PLoS One 2017;12(3):e0173635.
  7. Nagata N, Mishima H, Kurosawa S, Oba K, Sakamoto J. mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale. Clin Colorectal Cancer 2017; 16(2):154-157.e1.
  8. Shiga M, Maeda H, Oba K, Okamoto K, Namikawa T, Fujisawa K, Yokota K, Kobayashi M, Hanazaki K. Safety of laparoscopic surgery for colorectal cancer in patients over 80 years old: a propensity score matching study. Surg Today. 2017 Jan 27. [Epub ahead of print]
  9. Ikeda T, Uchida K, Yamauchi Y, Nagase T, Oba K, Yamada Y. Relationship between pre-anesthetic and intra-anesthetic airway resistance in patients undergoing general anesthesia: A prospective observational study. PLoS One 2017;12(2):e0172421.
  10. Nakamura M, Aoyama T, Ishibashi K, Tsuji A, Takinishi Y, Shindo Y, Sakamoto J, Oba K, Mishima H. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study). Cancer Chemother Pharmacol 2017;79:29-36.
  11. Denda T, Kanda M, Morita Y, Kim HM, Kashiwada T, Matsuda C, Fujieda S, Nakata K, Murotani K, Oba K, Sakamoto J, Mishima H. Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemother Pharmacol 2016;78:1253-1261.
  12. Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, Atsumi T, Manda N, Kurihara Y, Aoki S; SAIS Study Group. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PLoS One. 2016 Oct 6;11:e0164255.
  13. Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Ann Surg Oncol. 2016 Sep 8.
  14. Kozuma K, Kashiwabara K, Shinozaki T, Kozuma K, Oba K, Matsuyama Y. Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA). Int J Cardiovasc Imaging. 2017;33(6):779-787. doi: 10.1007/s10554-017-1068-4.
  15. Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T. Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-associated Colorectal Cancer. Gastroenterology. 2016 Aug 11. [Epub ahead of print].
  16. Furihata T, Kinugawa S, Fukushima A, Takada S, Homma T, Masaki Y, Abe T, Yokota T, Oba K, Okita K, Tsutsui H. Serum myostatin levels are independently associated with skeletal muscle wasting in patients with heart failure. Int J Cardiol 2016 ;220:483-7.
  17. Kusano M, Honda M, Okabayashi K, Akimaru K, Kino S, Tsuji Y, Watanabe M, Suzuki S, Yoshikawa T, Sakamoto J, Oba K, Saji S. Randomized controlled Phase III study comparing hepatic arterial infusion with systemic chemotherapy after curative resection for liver metastasis of colorectal carcinoma: JFMC 29–0003. J Can Res Ther 2016 [Epub ahead of print].
  18. Hazama S, Maeda H, Iwamoto S, Kim HM, Takemoto H, Kobayashi K, Sakamoto J, Nagata N, Oba K, Mishima H. A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study). Clin Colorectal Cancer. 2016 Jul 18. [Epub ahead of print]
  19. Matsui T, Nagata N, Hirata K, Okazaki S, Sato S, Nakamura M, Kim H, Oba K, Sakamoto J, Mishima H. Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial. Anticancer Res 2016;36:3437-43.
  20. Kusano M, Aoyama T, Okabayashi K, Hirata K, Tsuji Y, Nakamori S, Asahara T, Ohashi Y, Yoshikawa T, Sakamoto J, Oba K, Saji S. A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32). J Cancer Res Ther. 2016. [Epub ahead of print]
  21. Mabe K, Kato M, Oba K, Nakagawa S, Seki H, Katsuki S, Yamashita K, Ono S, Shimizu Y, Sakamoto N; Sapporo Consensus Study Group. A prospective, multicenter survey on the validity of shorter periendoscopic cessation of antithrombotic agents in Japan. J Gastroenterol. 2016 Apr 16. [Epub ahead of print]
  22. Noguchi K, Sakakibara M, Asakawa N, Tokuda Y, Kamiya K, Yoshitani T, Oba K, Miyauchi K, Nishizaki Y, Ogawa H, Yokoi H, Matsumoto M, Kitakaze M, Kimura T, Matsubara T, Ikari Y, Kimura K, Origasa H, Isshiki T, Morino Y, Daida H, Tsutsui H; PACIFIC investigators. Higher Hemoglobin A1c After Discharge Is an Independent Predictor of Adverse Outcomes in Patients With Acute Coronary Syndrome - Findings From the PACIFIC Registry. Circ J 2016;80:1607-14.
  23. Matsumoto M, Kato M, Oba K, Abiko S, Tsuda M, Miyamoto S, Mizushima T, Ono M, Omori S, Takahashi M, Ono S, Mabe K, Nakagawa M, Nakagawa S, Kudo T, Shimizu Y, Sakamoto N. Multicenter randomized controlled study to assess the effect of prophylactic clipping on post-polypectomy delayed bleeding. Dig Endosc. 2016 Mar 28. doi: 10.1111/den.12661.
  24. Kishikawa J, Kazama S, Oba K, Hasegawa K, Anzai H, Harada Y, Abe H, Matsusaka K, Hongo K, Oba M, Yasuda K, Otani K, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Hata K, Kawai K, Nozawa H, Yamaguchi H, Ishihara S, Sunami E, Ushiku T, Kitayama J, Fukayama M, Kokudo N, Watanabe T. CD133 Expression at the Metastatic Site Predicts Patients' Outcome in Colorectal Cancer with Synchronous Liver Metastasis. Ann Surg Oncol. 2016 Jan 29. [Epub ahead of print]
  25. Shimada H, Fukagawa T, Haga Y, Oba K. Does remnant gastric cancer really differ from primary gastric cancer? A systematic review of the literature by the Task Force of Japanese Gastric Cancer Association. Gastric Cancer 2016; 19(2):339-49.
  26. Oba K. Statistical challenges for central monitoring in clinical trials: a review. Int J Clin Oncol 2016;21(1):28-37.
  27. Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, Fukunaga M, Takagane A, Otsuji T, Miyake Y, Nagase M, Sakamoto J, Matsuoka M, Oba K, Mishima H. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer 2015;15:786.
  28. Matsuda C, Honda M, Tanaka C, Fukunaga M, Ishibashi K, Munemoto Y, Hata T, Bando H, Oshiro M, Kobayashi M, Tokunaga Y, Fujii A, Nagata N, Oba K, Mishima H. Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). Int J Clin Oncol. 2015 Oct 16. [Epub ahead of print]
  29. Soda H, Maeda H, Hasegawa J, Takahashi T, Hazama S, Fukunaga M, Kono E, Kotaka M, Sakamoto J, Nagata N, Oba K, Mishima H. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. BMC Cancer 2015;15:695.
  30. Asakawa N, Sakakibara M, Noguchi K, Kamiya K, Yamada S, Yoshitani T, Ono K, Oba K, Tsutsui H. Adaptive Servo-Ventilation Has More Favorable Acute Effects on Hemodynamics Than Continuous Positive Airway Pressure in Patients With Heart Failure. Int Heart J 2015;56:527-32.
  31. Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Miyoshi A, Kondo T, Tsuchida K, Atsumi T, Manda N, Kurihara Y, Aoki S; SAIS Study Group. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2). PLoS One. 2015 Aug 18;10(8):e0135854.
  32. Ishiguro N, Koseki N, Kaiho M, Kikuta H, Togashi T, Oba K, Morita K, Nagano N, Nakanishi M, Hazama K, Watanabe T, Sasaki S, Horino A, Kenri T, Ariga T; Hokkaido Pediatric Respiratory Infection Study Group. Regional Differences in Rates of Macrolide-Resistant Mycoplasma pneumoniae in Hokkaido, Japan. Jpn J Infect Dis. 2015 Jul 10. [Epub ahead of print]
  33. Tada N, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, Kitayama J, Oba K, Watanabe T. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. World J Surg Oncol 2015;13:30
  34. Matsushima M, Yabe I, Oba K, Sakushima K, Mito Y, Takei A, Houzen H, Tsuzaka K, Yoshida K, Maruo Y, Sasaki H. Comparison of Different Symptom Assessment Scales for Multiple System Atrophy. Cerebellum. 2015 Jun 21.
  35. Kotaka M, Yoshino T, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T. Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial). Cancer Chemother Pharmacol 2015;76:75-84.
  36. Abe Y, Kawakami H, Oba K, Hayashi T, Yasuda I, Mukai T, Isayama H, Ishiwatari H, Doi S, Nakashima M, Yamamoto N, Kuwatani M, Mitsuhashi T, Hasegawa T, Hirose Y, Yamada T, Tanaka M, Sakamoto N; Japan EUS-FNA Stylet Study Group. Effect of a stylet on a histological specimen in EUS-guided fine-needle tissue acquisition by using 22-gauge needles: a multicenter, prospective, randomized, controlled trial. Gastrointest Endosc 2015;82:837-844.
  37. Sakuhara Y, Nishio S, Morita K, Abo D, Hasegawa Y, Yuasa N, Mochizuki T, Soyama T, Oba K, Shirato H, Kudo K. Transcatheter Arterial Embolization with Ethanol Injection in Symptomatic Patients with Enlarged Polycystic Kidneys. Radiology 2015:141637.
  38. Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 2015 Apr 23.
  39. Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y. An open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci 2015;106:891-5.
  40. Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. Biom J. 2015 Feb 12. doi: 10.1002/bimj.201400049.
  41. Murai K, Akagi T, Shimosegawa K, Sugawara T, Ishizawa K, Ito S, Murai K, Motegi M, Yokoyama H, Noji H, Tajima K, Kimura J, Chou T, Ogawa K, Harigae H, Kubo K, Oba K, Sakamoto J, Ishida Y. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria. Eur J Haematol. 2015 Feb 19. doi: 10.1111/ejh.12536.
  42. Shinohara N, Obara W, Tatsugami K, Naito S, Kamba T, Takahashi M, Murai S, Abe T, Oba K, Naito S. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci. 2015 Feb 25. doi: 10.1111/cas.12646.
  43. Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol 2015;11:617-27.
  44. Fukushima A, Kinugawa S, Homma T, Masaki Y, Furihata T, Yokota T, Matsushima S, Takada S, Kadoguchi T, Oba K, Okita K, Tsutsui H. Serum Brain-Derived Neurotrophic Factor Level Predicts Adverse Clinical Outcomes in Patients with Heart Failure. J Card Fail 2015 Jan 29. doi: 10.1016/j.cardfail.2015.01.003.
  45. Arai Y, Aoyama T, Inaba Y, Okabe H, Ihaya T, Kichikawa K, Ohashi Y, Sakamoto J, Oba K, Saji S. Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study). Asia Pac J Clin Oncol 2015;11:41-8.
  46. Inokuchi K, Kumagai T, Matsuki E, Ohashi K, Shinagawa A, Hatta Y, Takeuchi J, Yoshida C, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Okamoto S, Oba K, Sakamoto J, Sakamaki H. Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase. J Clin Exp Hematop 2014;54:197-204.
  47. Fujita H, Hatanaka Y, Sutoh Y, Suzuki Y, Oba K, Hatanaka KC, Mitsuhashi T, Otsuka N, Fugo K, Kasahara M, Matsuno Y. Immunohistochemical Validation and Expression Profiling of NKG2D Ligands in a Wide Spectrum of Human Epithelial Neoplasms. J Histochem Cytochem 2014 Dec 3.
  48. Eguchi K, Honda M, Kataoka T, Mukouyama T, Tsuneto S, Sakamoto J, Oba K, Saji S. Efficacy of corticosteroids for cancer-related fatigue: A pilot randomized placebo-controlled trial of advanced cancer patients. Palliat Support Care 2014; 2014 Nov 5:1-8.
  49. Sakashita T, Homma A, Hatakeyama H, Mizumachi T, Kano S, Furusawa J, Iizuka S, Hoshino K, Hatanaka K, Oba K, Fukuda S. The potential diagnostic role of the number of ultrasonographic characteristics for patients with thyroid nodules evaluated as Bethesda I-V. Front Oncol 2014; 4:261.
  50. Kuwatani M, Kawakami H, Hayashi T, Eto K, Yamato H, Onodera M, Naruse H, Oba K. Effect of antispasmodic drugs on endoscopic ultrasound/endoscopic ultrasound-guided fine-needle aspiration: A multicenter randomized controlled trial. Endoscopic Ultrasound 2014; 3: 167-73.
  51. Tsunedomi R, Hazama S, Fujita Y, Okayama N, Kanekiyo S, Inoue Y, Yoshino S, Yamasaki T, Suehiro Y, Oba K, Mishima H, Sakamoto J, Hamamoto Y, Oka M. A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Clin Oncol 2014; 45: 1381-90.
  52. Kamiya K, Sakakibara M, Asakawa N, Yamada S, Yoshitani T, Iwano H, Komatsu H, Naya M, Chiba S, Yamada S, Manabe O, Kikuchi Y, Oyama-Manabe N, Oba K, Tsutsui H. Cardiac Magnetic Resonance Performs Better in the Detection of Functionally Significant Coronary Artery Stenosis Compared to Single-Photon Emission Computed Tomography and Dobutamine Stress Echocardiography. Circ J 2014; 78:2468-76.
  53. Nitta T, Mitsuhashi T, Hatanaka Y, Miyamoto M, Oba K, Tsuchikawa T, Suzuki Y, Hatanaka KC, Hirano S, Matsuno Y. Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray. Br J Cancer 2014;111:1363-72.
  54. Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol 2014;15:886-93
  55. Kono M, Yasuda S, Kato M, Kanetsuka Y, Kurita T, Fujieda Y, Otomo K, Horita T, Oba K, Kondo M, Mukai M, Yanai M, Fukasawa Y, Atsumi T. Long-term outcome in Japanese patients with lupus nephritis. Lupus 2014; 23:1124-32.
  56. Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, Fujieda Y, Oku K, Bohgaki T, Amengual O, Horita T, Atsumi T. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford). 2014 Apr 24.
  57. Nakai Y, Inoue T, Toda H, Toyomaki A, Nakato Y, Nakagawa S, Kitaichi Y, Kameyama R, Hayashishita Y, Wakatsuki Y, Oba K, Tanabe H, Kusumi I. The influence of childhood abuse, adult stressful life events and temperaments on depressive symptoms in the nonclinical general adult population. J Affect Disord 2014; 158: 101-7.
  58. Maeda H, Hazama S, Shavkat A, Okamoto K, Oba K, Sakamoto J, Takahashi K, Oka M, Nakamura D, Tsunedomi R, Okayama N, Mishima H, Kobayashi M. Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations. Mol Diagn Ther 2014; 18: 333-42.
  59. Iwamoto S, Hazama S, Kato T, Miyake Y, Fukunaga M, Matsuda C, Bando H, Sakamoto J, Oba K, Mishima H. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. Anticancer Res 2014; 34: 1967-73.
  60. Cho H, Yoshikawa T, Oba MS, Hirabayashi N, Shirai J, Aoyama T, Hayashi T, Yamada T, Oba K, Morita S, Sakamoto J, Tsuburaya A. Matched pair analysis to examine the effects of a planned preoperative exercise program in early gastric cancer patients with metabolic syndrome to reduce operative risk: The adjuvant exercise for general elective surgery (AEGES) study group. Ann Surg Oncol 2014; 21: 2044-50.
  61. Kumagai T, Matsuki E, Inokuchi K, Ohashi K, Shinagawa A, Takeuchi J, Yoshida C, Okamoto S, Wakita H, Kozai Y, Shirasugi Y, Fujisawa S, Iwase O, Yano S, Nishiwaki K, Oba K, Sakamoto J, Sakamaki H. Relative increase in lymphocytes from as early as one month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol 2014; 99: 41-52.
  62. Fukudome I, Kobayashi M, Dabanaka K, Maeda H, Okamoto K, Okabayashi T, Baba R, Kumagai N, Oba K, Fujita M, Hanazaki K. Diamine oxidase as a marker of intestinal mucosal injury and the effect of soluble dietary fiber on gastrointestinal tract toxicity after intravenous 5-fluorouracil treatment in rats. Med Mol Morphol 2014;47:100-7.
  63. Koseki N, Kaiho M, Kikuta H, Oba K, Togashi T, Ariga T, Ishiguro N. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season. Influenza and Other Respiratory Viruses 2014;8:151-8
  64. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014;17:26-33
  65. Sasaki H, Matsushima M, Hama Y, Sakushima K, Nakamura M, Yabe I, Oba K, Tanji K, Mori F, Wakabayashi K, Kakita A, Takahashi H, Utsumi J. Plasma matrix metalloproteinase-3 correlates with the clinical severity in men with multiple system atrophy. Neurology and Clinical Neuroscience 2013;1:69-77.
  66. Hirata K, Nagata N, Kato T, Okuyama Y, Ando H, Takahashi K, Oba K, Sakamoto J, Hazama S, Mishima H. Prospective Phase II Trial of Second-line FOLFIRI in Patients with Advanced Colorectal Cancer Including Analysis of UGT1A1 Polymorphisms -A FLIGHT-2 study-. Anticancer Res 2013; 104:1662-9.
  67. Tanaka J, Morishima Y, Takahashi Y, Yabe T, Oba K, Takahashi S, Taniguchi S, Ogawa H, Onishi Y, Miyamura K, Kanamori H, Aotsuka N, Kato K, Kato S, Atsuta Y, Kanda Y. Effects of KIR-ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. Blood Cancer Journal 2013; 3:e164.
  68. Oba K, Paoletti X, Alberts S, Bang Y, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent DJ, Shitara K, Van Cutsem E, Buyse M, Burzykowski T. Disease Free Survival as a surrogate for Overall Survival in adjuvant trials of gastric cancer: A meta-analysis. J Natl Cancer Inst 2013; 105: 1600-7.
  69. Paoletti X, Oba K, Bang Y, Bleiberg H, Boku N, Bouche O, Catalano P, Fuse N, Michiels S, Moehler M, Morita S, Ohashi Y, Ohtsu A, Roth A, Rougier P, Sakamoto J, Sargent DJ, Sasako M, Shitara K, Thuss-Patience P, Van Cutsem E, Burzykowski T, Buyse M. Progression-Free Survival As A Surrogate For Overall Survival In Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. J Natl Cancer Inst 2013; 105: 1667-70.
  70. Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated mCRC in two prospective studies in Japan. Cancer Sci 2013; 104:1662-9.
  71. Fukushima A, Kinugawa S, Homma T, Masaki Y, Furihata T, Yokota T, Matsushima S, Abe T, Suga T, Takada S, Kadoguchi T, Katsuyama R, Oba K, Okita K, Tsutsui H. Decreased serum brain-derived neurotrophic factor levels are correlated with exercise intolerance in patients with heart failure. Int J Cardiol 2013;168:e142-4.
  72. Mitsui N, Asakura S, Shimizu Y, Fujii Y, Kako Y, Tanaka T, Oba K, Inoue T, Kusumi I. Temperament and character profiles of Japanese university students with depressive episodes and ideas of suicide or self-harm: A PHQ-9 screening study. Compr Psychiatry 2013; 54: 1215-21.
  73. Tanaka J, Kanamori H, Nishiwaki S, Ohashi K, Taniguchi S, Eto T, Nakamae H, Minagawa K, Miyamura K, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishimoto N, Oba K, Masauzi N. Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Bone Marrow Transplant 2013;48:1389-94.
  74. Shinohara N, Maruyama S, Shimizu S, Nishioka K, Abe T, C-Hatanaka K, Oba K, Nonomura K, Shirato H. Longitudinal comparison of quality of life after real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer. J Radiat Res 2013; 54: 1095-101.
  75. Osawa T, Shinohara N, Maruyama S, Oba K, Abe T, Maru S, Takada N, Sazawa A, Nonomura K. Long-term renal function outcomes in bladder cancer after radical cystectomy. Urol J 2013;10:784-9.
  76. Tsuburaya A, Nagata N, Cho H, Hirabayashi N, Kobayashi M, Kojima H, Munakata Y, Fukushima R, Kameda Y, Shimoda T, Oba K, Sakamoto J. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol 2013; 71: 1309-14.
  77. Osawa T, Harada H, Oba K, Seki T, Togashi M. Clinical factor affecting the recovery of kidney function in clinically localized renal cell carcinoma patients who underwent nephron-sparing surgery. Hokkaido Igaku Zasshi 2013;88:15-20.
  78. Yamada S, Sakakibara M, Yokota T, Kamiya K, Asakawa N, Iwano H, Yamada S, Oba K, Tsutsui H. Acute hemodynamic effects of adaptive servo-ventilation in patients with heart failure. Circ J 2013;77:1214-20.
  79. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group; Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Shitara K, Tsuburaya A, Van Cutsem E, Buyse M. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer 2013;49:1565-77.
  80. Taguchi T, Yamamoto D, Masuda N, Oba K, Nakayama T, Nagata T, Nomura M, Yoshidome K, Yoshino H, Matsunami N, Miyashita M, Furuya Y, Ishida T, Wakita K, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group (KBCSG). Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609. Cancer Chemother Pharmacol 2013 ;71:741-7.
  81. Kato T, Ishikawa K, Aragaki M, Sato M, Okamoto K, Ishibashi T, Oba K, Kaji M. Optimal predictive value of preoperative serum carcinoembryonic antigen for surgical outcomes in stage I non-small cell lung cancer: differences according to histology and smoking status. J Surg Oncol 2013;107:619-24.
  82. Nakatsumi H, Komatsu Y, Yuki S, Sogabe S, Tateyama M, Muto S, Kudo M, Kato K, Miyagishima T, Uebayashi M, Meguro T, Oba K, Asaka M. Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. Chemotherap 2012;58:439-44.
  83. Kobayashi M, Hazama S, Takahashi K, Oba K, Okayama N, Nishioka M, Hinoda Y, Oka M, Okamoto K, Maeda H, Nakamura D, Sakamoto J, Mishima H. Is there diversity among UGT1A1 polymorphism in Japan? World J Gastrointest Oncol 2012;4:170–5.
  84. Sakakibara M, Yamada S, Kamiya K, Yokota T, Oba K, Tsutsui H. Sleep-Disordered Breathing Is an Independent Risk Factor of Aborted Sudden Cardiac Arrest in Patients With Coronary Artery Spasm. Circ J 2012;76:2204-10.
  85. Iwami D, Harada H, Morita K, Oba K, Fukuzawa N, Hotta K, Sasaki H, Miyazaki C, Nonomura K. Preservation of Deep Inferior Epigastric Artery at Kidney Transplantation Prevents Atrophy of Lower Rectus Abdominis Muscle. Transplantation. 2012;93:1013-6.
  86. Shinohara N, Nonomura K, Abe T, Maruyama S, Kamai T, Takahashi M, Tatsugami K, Yokoi S, Deguchi T, Kanayama H, Oba K, Naito S. A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma. Cancer Sci 2012;103:1695-700.
  87. Sakamoto J, Oba K. Geographic difference in advanced gastric cancer prevalence and chemotherapy treatment results: could it really be an independent prognostic factor? Gastric Cancer. 2012;15:232-4.
  88. Shinohara N, Abe T, Mochizuki T, Kashiwagi A, Kanagawa K, Maruyama S, Sazawa A, Oba K, Nonomura K. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol 2011; 31: 1276-82.
  89. Ogihara T, Nakao K, Ueshima K, Oba K, Yasuno S, Fujimoto A, Matsuoka H, Saruta T, on behalf of the CASE-J Ex Study Group. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex). Hypertens Res 2011;34:1295-301.
  90. Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I, Maehara Y. Bevacizumab-containing therapy (5 mg/kg or 10 mg/kg) and FOLFIRI in advanced colorectal cancer failed to bevacizumab plus oxaliplatin-based therapy: A Phase III Study (EAGLE Study). Jpn J Clin Oncol 2011;42(2):134-8.
  91. Ueshima K, Oba K, Yasuno S, Fujimoto A, Tanaka S, Ogihara T, Saruta T, Nakao K. Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients: primary and secondary prevention of ischemic heart disease in a subanalysis of the CASE-J (Candesartan Antihypertensive Survival Evaluation in Japan) trial. Circ J 2011; 75: 2411-6.
  92. Nishimura R, Nakamura S, Oba K, Komoike Y, Mitsuyama S, Hisamatsu K, Oriuchi N, Abe C, Kuwayama T, Taguchi T, Sakamoto J, Noguchi S. Prospective study on the effect of toremifene in patients with adjuvant anastrozole failure in postmenopausal breast cancer. Ann Cancer Res Ther 2011; 1: 9-14.
  93. Hara T, Nishikawa K, Sakatoku M, Oba K, Sakamoto J, Omura K. Phase II study of weekly paclitaxel, cisplatin and 5-fluorouracil for advanced gastric cancer. Gastric Cancer 2011; 14: 332-8.
  94. Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K, Sakamoto J, Mishima H. Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms. Jpn J Clin Oncol 2011;41: 477-82.
  95. Oba K, Sato T, Ogihara T, Saruta T, Nakao K. How to use marginal structural models in randomized trials to estimate the natural direct and indirect effects of therapies mediated by causal intermediates. Clin Trials 2011; 8: 277-87.
  96. Imamoto H, Oba K, Sakamoto J, Iishi H, Narahara H, Yumiba T, Morimoto T, Nakamura M, Oriuchi N, Kakutani C, Morita S, Shiozaki H. Assessing Clinical Benefit Response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer. Gastric Cancer 2011; 14: 81-90.
  97. Oba K, Matsuoka M, Satoh T, Muro K, Oriuchi N, Sakamoto J, Mishima H. Multicentre Phase II Study of XELOX with Bevacizumab in Late-stage Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancer: An ASCA Study. Jpn J Clin Oncol 2011; 41: 134-8.
  98. Krotov NF, Rasulov AE, Almardonov RB, Madiyarov BT, Chernishova TB, Oba K, Mamarajabov SE. Antireflux cervical esophagogastricoanastomosis in the surgery of esophageal cancer. Ann Cancer Res Ther 2010; 18: 59-64.
  99. Ueshima K, Yasuno S, Oba K, Fujimoto A, Mukoyama M, Ogihara T, Saruta T, Nakao K. Impact of Left Ventricular Hypertrophy on the Time-course of Renal Function in Hypertensive Patients: A Subanalysis of the CASE-J Trial. Circ J 2010; 74: 2132-8.
  100. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-analysis. JAMA 2010; 303: 1729-37.
  101. Zamani S, Farnia M, Torknejad A, Alaei BA, Gholizadeh M, Kasraee F, Kihara MO, Oba K, Kihara M. Patterns of drug use and HIV-related risk behaviors among incarcerated people in a prison in Iran. J Urban Health 2010; 87: 603-16.
  102. Yasuno S, Oba K, Ueshima K, Fujimoto A, Hirata M, Ogihara T, Saruta T, Nakao K. Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients? : A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Diabetes Care 2010; 33: 1122-7.
  103. Nakao K, Hirata M, Oba K, Yasuno S, Ueshima K, Fujimoto A, Ogihara T, Saruta T. Role of diabetes and obesity on outcomes of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Hypertens Res 2010; 33:600-6.
  104. Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama T, Azuma J, Ogihara T, Saruta T, Nakao K, for the CASE-J trial Group. Long-term Effects of Candesartan and Amlodipine on Cardiovascular Mortality and Morbidity in Japanese High-risk Hypertensive Patients: Rationale, Design, and Characteristics of Candesartan Antihypertensive Survival Evaluation in Japan Extension (CASE-J Ex). Contemp Clin Trials 2009; 30: 97-101.
  105. Ogihara T, Saruta T, Rakugi H, Fujimoto A, Ueshima K, Oba K, Takeda K, Higaki J, Nakao K, on behalf of the CASE-J Trial Group. Optimal Blood Pressure for Prevention of Cardiovascular Events in Hypertensive Patients with Complications: a subanalysis of the CASE-J trial. Hypertens Res 2009; 32: 248-54.
  106. Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: Update of a meta-analysis. Int J Clin Oncol 2009; 14:85-9.
  107. Yoshikawa T, Tsuburaya A, Hirabayashi N, Yoshida K, Nagata N, Kodera Y, Takahashi N, Oba K, Kimura M, Ishikura S, Miyashita Y, Sakamoto J. A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma. Cancer Chemother Pharmacol 2009; 64: 1071-7.
  108. Ueshima K, Yasuno S, Oba K, Fujimoto A, Ogihara T, Saruta T, Nakao K. Effects of Cardiac Complications on Cardiovascular Events in Japanese High-Risk Hypertensive Patients. Circ J 2009; 73: 1080-5.
  109. Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of immunochemotherapy with lentinan for patients with unresectable/recurrent gastric cancer: An individual-patient-based meta-analysis of randomized controlled clinical trials. Anticancer Res 2009; 29:2739-45.
  110. Yasuno S, Ueshima K , Oba K, Fujimoto A, Ogihara T, Saruta T, Nakao K. Clinical significance of left ventricular hypertrophy and changes of left ventricular mass in high-risk hypertensive patients: An analysis of CASE-J trial. J Hypertens 2009; 27: 1705-12.
  111. Nagata N, Kondo K, Shibata Y, Kato T, Okuyama Y, Ikenaga M, Tanemura H, Oba K, Sakamoto J, Mishima H. Multicenter Phase II Study of FOLFOX for Metastatic Colorectal Cancer in Japan: SWIFT-1 & 2 study. Hepatogastroenterology 2009 ;56: 1346-53.
  112. Kobayashi M, Tsuburaya A, Nagata N, Miyashita Y, Oba K, Sakamoto J. A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. Gastric Cancer 2006; 9: 114-9.
  113. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: CASE-J trial. Hypertension 2008; 51: 393-8.
  114. Cho H, Tsuburaya A, Sakamoto J, Morita S, Oba K, Yoshikawa T, Miyajima N; Adjuvant Exercise for General Elective Surgery (AEGES) Study Group. A randomized phase II trial of preoperative exercise to reduce operative risk in gastric cancer patients with metabolic syndrome: adjuvant exercise for general elective surgery (AEGES) study group. Jpn J Clin Oncol 2008; 38: 71-3.
  115. Morita S, Kaptain AA, Oba K, Sakamoto J. Domain Structure of the EORTC QLQ-STO22 Supported by Japanese Validation Data. Psychooncology 2008; 17: 474-9.
  116. Ogihara T, Nakao K, Fukui T, Fukiyama K, Fujimoto A, Ueshima K, Oba K, Shimamoto K, Matsuoka H, Saruta T, for the CASE-J Trial Group. The optimal target blood pressure for antihypertensive treatment in the Japanese elderly patients with high-risk hypertension: a subanalysis of CASE-J trial. Hypertens Res 2008; 31: 1595-601.
  117. Sakamoto J, Hamada C, Yoshida S, Kodaira S, Yasutomi M, Kato T, Oba K, Nakazato H, Saji S, Ohashi Y. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Brit J Cancer 2007; 96: 1170-7.
  118. Kobayashi M, Oba K, Sakamoto J, Kondo K, Nagata N, Okabayashi T. Pharmacokinetic study of paclitaxel of weekly administration dose in advanced or recurrent gastric cancer patients in Japan. Gastric Cancer 2007; 10:52-7.
  119. Ninomiya M, Kondo K, Matsuo K, Hirabayashi N, Kojima H, Kobayashi M, Kawamura S, Ando T, Musha N, Konno H, Nagata N, Usuki H, Miyashita Y, Oba K, Morita S, Sakamoto J. Multicenter Phase II Trial of Combination Chemotherapy with Weekly Paclitaxel and 5-Fluorouracil for the Treatment of Advanced or Recurrent Gastric Carcinoma. J Chemotherapy 2007; 19:444-50.
  120. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Efficacy of Adjuvant Immunochemotherapy with Polysaccharide K for Patients with Curative Resections of Gastric Cancer. Cancer Immunol Immun 2007; 56:905-11.
  121. Oba K, Morita S, Rahman M, Sakamoto J. Factors associated with compliance and non-compliance by physicians in a large-scale randomized clinical trial. Trials 2006; 7:26.
  122. Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J. Efficacy of Adjuvant Chemotherapy Using Oral Fluorinated Pyrimidines for Curatively Resected Gastric Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials in Japan. J Chemother 2006; 18: 311-7.
  123. Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H, Ohashi Y; Meta-Analysis Group of the Japanese Society for Cancer of the Colon Rectum. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 2006; 55: 404-11.
  124. Sakamoto J, Oba K, Matsui T, Kobayashi M. Efficacy of Oral Anti-Cancer Agents for Colorectal Cancer. Dis Colon Rectum 2006; 49 Suppl 1: S82-91.
  125. Morita S, Kobayashi M, Oba K, Ichihara T, Nakao A, Sakamoto J. Truth-telling to Patients with Advanced Cancer: A Comparison between Cancer center, University Hospitals, General City Hospitals, and Private General Practitioners in Japan. Ann Cancer Res Therap 2006; 14: 1-11.

論文(和文)

  1. 大庭幸治. ネットワークメタアナリシス:Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Coronary intervention 2017; 13(3): 56-62.
  2. 大庭幸治. 臨床研究のための統計学講座(第6回)論文の内容を吟味する時の統計学的なポイントを押さえよう. Rheumatology clinical research : journal of rheumatology clinical research 2016; 5(3): 213-216.
  3. 大庭幸治. 臨床研究のための統計学講座(第5回)応用的な解析方法について理解しよう : 繰り返し測定データの解析. Rheumatology clinical research : journal of rheumatology clinical research 2016; 5(2): 136-139.
  4. 大庭幸治. 臨床研究のための統計学講座(第4回)基本的な解析方法について理解しよう(2)重回帰分析やロジスティック回帰分析. Rheumatology clinical research : journal of rheumatology clinical research 2016; 5(1): 59-62.
  5. 大庭幸治. 臨床研究のための統計学講座(第3回)基本的な解析方法を理解しよう : 平均値の比較を中心に. Rheumatology clinical research : journal of rheumatology clinical research 2015; 4(3): 211-214.
  6. 大庭幸治. 臨床研究のための統計学講座(第2回)研究に必要な人数の計算方法を理解しよう : 統計的仮説検定とサンプルサイズ. Rheumatology clinical research : journal of rheumatology clinical research 2015; 4(2): 136-139.
  7. 大庭幸治. 臨床研究のための統計学講座(第1回)研究論文で目にする統計用語を理解しよう : 統計の基本用語からp値まで. Rheumatology clinical research : journal of rheumatology clinical research 2015; 4(1): 59-63.
  8. 大庭幸治. おさえておきたい基本の統計学知識 (特集 看護研究のイロハを学ぼう!). 循環器ナーシング : 基礎知識から最新トピックスまで!ハートナースとコメディカルのための循環器看護専門誌 2016; 6(12): 69-75.
  9. 大庭幸治. 非劣性試験のピットフォールPitfalls of non-inferiority trials. 循環器内科 2016; 79(3): 262-266.
  10. 大庭幸治. 胃がん臨床試験の個人データに基づくメタアナリシス. 胃がんperspective 2015;8:20-7.
  11. 出合美帆 大庭幸治 村元綾子 関口真理 佐々木由紀 橋本あきら 寺元剛 佐藤典宏. 北海道大学病院における自主臨床研究の臨床研究コーディネーター支援業務に関する アンケート調査. Jpn Pharmacol Ther 2014; 42:s154-9
  12. 佐久嶋研 大庭幸治 西村千佳子 佐藤典宏 梅木玲緒奈. 多職種協同による病院情報システム・電子カルテデータを臨床研究に活用するプロセス.情報処理学会デジタルプラクティス 2013; 4: 244-50.
  13. 保野慎治, 上嶋健治, 大庭幸治, 中尾葉子, 笠原正登, 藤本明, 宮脇尚志, 桝田出, 中尾一和. 慢性腎臓病発症予測因子の検討 人間ドックデータベースから見た生活習慣病の関わり. 健康管理事業団研究助成論文集 2011; XXVII: 19-27.
  14. 小林純子, 上嶋健治, 大江陽子, 福富まさ美, 井上房子, 高木真理子, 中本まり子, 藤堂祥子, 長谷部美代子, 山中真由美, 大庭幸治, 田中佐智子, 保野慎治, 藤本明, 中尾一和. CASE-J Ex試験への継続参加医師の背景因子について. 臨床評価 2011; 39: 407-12.
  15. 大庭幸治. メタ解析はオールマイティか. HeartView 2011; 15: 34-9.
  16. 上嶋健治, 大庭幸治, 田中佐智子, 保野慎治, 藤本明, 中尾一和. 日本人高血圧患者の心血管系イベント発症に及ぼすACE阻害薬およびARBの影響 – メタアナリシスからの検討 –. 循環器専門医 2011; 19: 25-33.
  17. 大江陽子, 上嶋健治, 大庭幸治, 福富まさ美, 井上房子, 高木真理子, 中本まり子, 小林純子, 保野慎治, 藤本明, 中尾一和. 臨床試験の症例登録は一部の参加医師により大部分がなされるのか?:CASE-J試験によるパレートの法則の検証. 臨床評価 2011; 38: 885-90.
  18. 田中司朗, 大庭幸治, 吉村健一, 手良向聡. 代替エンドポイントの評価のための統計的基準とその適用事例. 計量生物学会誌 2010; 31: 23-48.
  19. 坂本純一, 森田智視, 大庭幸治. DFSとOSの相関:大腸がん補助化学療法 – surrogate endpointの探索と留意点–. 腫瘍内科 2009; 4: 433-44.
  20. Hirata M, Oba K, Ueshima K, Nakao K. Obesity in CASE-J Study. 日本臨床 2009; 67:404-7.
  21. 大庭幸治. CASE-J -CASE-J Studyの軌跡- CASE-Jの参加医師について-誰が参加し、なぜ参加したのか?-. 日本臨床 2008; 66: 28-32.
  22. 佐藤俊哉 森田智視 大庭幸治. CASE-J -CASE-J Studyの軌跡- 医療統計家の役割. 日本臨床 2008; 66: 51-55.
  23. 上嶋健治 大庭幸治 保野慎治 藤本明 中尾一和. 臨床試験におけるEBM研究センターの役割:CASE-J試験を題材に. 循環器科 2008; 64: 266-70.
  24. 大橋靖雄 石塚直樹 大庭幸治 広崎真史 折笠秀樹. データマネージメントの難しさ‐今後のあり方(座談会). 動脈硬化予防 2008; 6: 52-67.
  25. 平田雅一 上嶋健治 大庭幸治 中尾一和. CASE-J-肥満- RASの新知見. Angiotensin Research 2007; 4:142-4.
  26. 上嶋健治 大庭幸治 保野慎治 藤本明 中尾一和. 臨床研究・基礎研究からみた循環器疾患予防の観点 CASE-J試験から学ぶもの. 日本循環器病予防学会誌2007; 42: 112-6.
  27. 上嶋健治 大庭幸治 中尾一和. 循環器研究のあたらしい潮流: CASE-J研究. 医学のあゆみ 2007; 220:531-7.
  28. 坂本純一 大庭幸治 小林道也 弓場健義. 腹膜播種の先進医療. 臨床外科 2006; 61: 769-774.
  29. 坂本純一 大庭幸治 松井隆則 小林道也. バイオセラピィに関するEBM.  Biotherapy 2006; 20: 363-373.
  30. 坂本純一 大庭幸治. EBMにおけるランダム化比較試験. 天理医学紀要 2005; 8: 90-91.
  31. 大庭幸治 大橋靖雄. Regression Dilution. 動脈硬化予防2005; 4: 70-72.
  32. 松山裕 大庭幸治. Clinical Bioinformatics 統計解析の実際. Surgery Frontier 2004; 4: 82-89.
  33. 大津洋 大庭幸治. Clinical Bioinformatics臨床試験におけるデータマネジメント. Surgery Frontier 2004; 4: 90-93.

  1. Nozaki T, Kashiwabara K, Shinozaki T, Oba K, Matsuyama Y, Ota E, Mori R. A network meta-analysis of prophylactic antibiotics for preventing post-cesarean endometritis. At: The 24th Cochrane Colloquium, Seoul, Korea. October 23–27, 2016.
  2. Yoshida K, Tsuburaya A, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Kurita A, Kojima H, Miyashita Y, Oba K, Buyse ME, Morita S, Sakamoto J. SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer. Oral Abstract Session, Gastrointestinal (Noncolorectal) Cancer 2013 ASCO Annual Meeting.
  3. Oba K, Burzykowski T. Validation of a surrogate endpoint by using the meta-analytic approach when the true endpoint is a rare binary-event. 34th Annual Conference of the International Society for Clinical Biostatistics 25 – 29 August 2013 in Munich, Germany.

シンポジウム(国内)

  1. 大庭幸治. 観察研究データを用いた予測モデルの構築, 2016年度ARO協議会第4回学術集会, 大阪, 2016年8月29-31日.
  2. 伊藤陽一 大庭幸治.  アカデミアにおける統計家による研究支援体制(国内), 2015年度統計関連学会連合大会, 岡山, 2015年9月6-9日.

  1. Oba K, Paoletti X. Evaluation of Surrogate Endpoints using a Meta-Analysis Approach with Individual Patient Data: Summary of a Gastric Cancer Meta-Analysis Project. In: Matsui S, Crowley J(Eds.) Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, Singapore, 2017
  2. Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A,Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints in cancer clinical trials. In: Oncology Clinical Trials: Successful Design, Conduct and Analysis. Second Edition, Demos Medical Publishing, NY, 2017

著書等(和文)

  1. 平田雅一 上嶋健治 大庭幸治 中尾一和:糖尿病に関する最近の治験:大規模臨床試験 分子糖尿病学の進歩 基礎から臨床まで 監修 矢崎義雄 清野進 渥美義仁 門脇孝 春日雅人 編 p124-128 金原出版 東京 2008
  2. 大庭 幸治 他 (訳者11名):医学研究のための多変量解析一般回帰モデルからマルチレベル解析まで 木原雅子 木原正博 監訳 メディカルサイエンスインターナショナル 東京 2008
  3. 坂本純一 大庭幸治 小寺泰弘:胃癌の術後補助化学療法 別冊医学のあゆみ 消化器疾患ver.3 – state of arts I. 消化管 (食道・胃・腸) 編集 市倉隆 日比紀文 p585-587 医歯薬出版株式会社 東京 2006
  4. 坂本純一 松井隆則 大庭幸治:胃癌・大腸癌の術後補助化学療法 消化器がん化学療法2006 編集 市倉隆 p219-228 日本メディカルセンター 東京 2006

TOP